Covered recipient · General Payments record
HONEYLYNN CATUBLAS ABAYA
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2022–2024
$1,544.38
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $555.95 | 15 |
| Education | $24.61 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ardelyx, Inc. | $237.66 | 5 |
| Amgen Inc. | $162.56 | 2 |
| AKEBIA THERAPEUTICS INC | $57.51 | 3 |
| Novo Nordisk AS | $40.24 | 2 |
| Fresenius USA Marketing, Inc. | $39.44 | 2 |
| Acerta Pharma LLC | $29.44 | 1 |
| Medtronic, Inc. | $13.71 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $13.65 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145827948 | CMS |
| AKEBIA THERAPEUTICS INC | $19.25 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145828444 | CMS |
| AKEBIA THERAPEUTICS INC | $24.61 | 08/13/2024 | Education | Undisputed | 01/23/2026 | 1145832803 | CMS |
| Amgen Inc. | $134.63 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115406056 | CMS |
| Amgen Inc. | $27.93 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115406052 | CMS |
| Ardelyx, Inc. | $125.00 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715887 | CMS |
| Ardelyx, Inc. | $8.93 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715889 | CMS |
| Ardelyx, Inc. | $11.80 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715891 | CMS |
| Ardelyx, Inc. | $80.59 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715893 | CMS |
| Ardelyx, Inc. | $11.34 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715895 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.44 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105202542 | CMS |
| Fresenius USA Marketing, Inc. | $15.00 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154206746 | CMS |
| Fresenius USA Marketing, Inc. | $24.44 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154206748 | CMS |
| Medtronic, Inc. | $13.71 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116958986 | CMS |
| Novo Nordisk Inc | $20.00 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100522487 | CMS |
| Novo Nordisk Inc | $20.24 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100566100 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.